← Back to Discover
Foresite Capital Management VI LLC
Period ended Jun 30, 2026 · Latest filing Aug 14, 2026
These quarterly holdings are delayed and may not include all assets or short positions.
Values are from the reporting date, not current prices or purchase costs.
The same security may appear in multiple rows.
Source: SEC
Reported portfolio value
Quarter-end reported holdings; not current value or investment performance.
View reported values
- Jun 30, 2026: $642,575,985
More quarters will appear as history becomes available.
Top holdings
Top 10 at Jun 30, 2026. Matching entries are combined; security classes and options remain separate. Shares exclude principal amounts; option shares reflect the reported underlying amount.
View top holdings values
- CG Oncology, Inc. · COM · 156944100 · shares: $168,358,233
- ALUMIS INC. · COM · 022307102 · shares: $119,529,434
- Seaport Therapeutics, Inc. · COM · 81221K108 · shares: $38,651,196
- Denali Therapeutics Inc. · COM · 24823R105 · shares: $35,924,950
- Celldex Therapeutics, Inc. · COM · 15117B202 · shares: $32,734,121
- AGIOS PHARMACEUTICALS, INC. · COM · 00847X104 · shares: $29,131,350
- Corvus Pharmaceuticals, Inc. · COM · 221015100 · shares: $27,358,621
- Parabilis Medicines, Inc. · COM · 698955101 · shares: $27,343,834
- GH Research PLC · ORD · G3855L106 · shares: $25,280,452
- Jade Biosciences, Inc. · COM · 008064206 · shares: $19,701,741
Reported holdings
23 reported entries| Issuer | Class | CUSIP | Type | Shares / principal | Reported value (USD) |
|---|---|---|---|---|---|
| CG Oncology, Inc. | COM | 156944100 | — | 2,369,574 shares | $168,358,233 |
| ALUMIS INC. | COM | 022307102 | — | 4,247,670 shares | $119,529,434 |
| Seaport Therapeutics, Inc. | COM | 81221K108 | — | 1,779,521 shares | $38,651,196 |
| Denali Therapeutics Inc. | COM | 24823R105 | — | 1,396,771 shares | $35,924,950 |
| Celldex Therapeutics, Inc. | COM | 15117B202 | — | 879,713 shares | $32,734,121 |
| AGIOS PHARMACEUTICALS, INC. | COM | 00847X104 | — | 785,000 shares | $29,131,350 |
| Corvus Pharmaceuticals, Inc. | COM | 221015100 | — | 1,831,233 shares | $27,358,621 |
| Parabilis Medicines, Inc. | COM | 698955101 | — | 999,044 shares | $27,343,834 |
| GH Research PLC | ORD | G3855L106 | — | 940,493 shares | $25,280,452 |
| Jade Biosciences, Inc. | COM | 008064206 | — | 886,667 shares | $19,701,741 |
| Hinge Health, Inc. | CL A | 433313103 | — | 220,400 shares | $18,293,200 |
| Kymera Therapeutics, Inc. | COM | 501575104 | — | 146,332 shares | $16,779,890 |
| AtaiBeckley Inc. | COM | 04650F101 | — | 2,750,000 shares | $14,492,500 |
| Verastem, Inc. | COM | 92337C203 | — | 3,146,631 shares | $12,020,130 |
| Beam Therapeutics Inc. | COM | 07373V105 | — | 330,000 shares | $11,325,600 |
| Minerva Neurosciences, Inc. | COM | 603380205 | — | 1,985,584 shares | $11,019,991 |
| ArriVent BioPharma, Inc. | COM | 04272N102 | — | 301,341 shares | $10,468,586 |
| Aura Biosciences, Inc. | COM | 05153U107 | — | 1,333,334 shares | $9,466,671 |
| Crinetics Pharmaceuticals, Inc. | COM | 22663K107 | — | 212,010 shares | $7,933,414 |
| Research Alliance Corp III | CL A | G75226103 | — | 300,000 shares | $3,210,000 |
| Zura Bio Ltd | CL A | G9TY5A101 | — | 450,000 shares | $2,655,000 |
| Kailera Therapeutics, Inc. | COM | 482931102 | — | 37,500 shares | $826,125 |
| Disc Medicine, Inc. | COM | 254604101 | — | 970 shares | $70,946 |